Pfizer (PFE) PT Lowered to $36 at JPMorgan

Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer

NEW YORK--(BUSINESS WIRE)-- As announced today by the Austrian Breast & Colorectal Cancer Study Group and the Alliance Foundation Trials, LLC, Pfizer Inc. (NYSE: PFE) reports that following a preplanned efficacy and futility analysis, the independent Data Monitoring Committee (DMC) of the collaborative Phase 3 early breast cancer PALbociclib CoLlaborative Adjuvant Study (PALLAS) determined that the trial is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival (iDFS). Patients currently receiving palbociclib in the study will be advised about next steps by... More

Final PROSPER Results Show XTANDI® (enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer

NEW YORK and TOKYO, May 29, 2020 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") have announced final results from the overall survival (OS) analysis of the Phase 3 PROSPER trial, which evaluated XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) versus placebo plus ADT in men with non-metastatic... More

XTANDI® (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis

TOKYO, May 29, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has approved XTANDI® (enzalutamide), an oral androgen receptor signaling inhibitor, for the treatment of prostate cancer patients with distant metastasis. With this approval, XTANDI is now indicated for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), a form of prostate cancer that has spread to other parts of the body and still responds to a medical or surgical treatment that lowers testosterone.1,2 This is in addition to an existing indication... More

Corning and Pfizer Announce Supply Agreement for Corning Valor® Glass Packaging

CORNING, NY, May 28, 2020 (GLOBE NEWSWIRE) -- Corning Incorporated (NYSE: GLW) and Pfizer Inc. (NYSE: PFE) today announced the execution of a long-term purchase and supply agreement for Corning Valor® Glass.

The multiyear agreement provides for the supply of Valor... More

Corning and Pfizer Announce Supply Agreement for Corning Valor® Glass Packaging

CORNING, NY, May 28, 2020 (GLOBE NEWSWIRE) -- Corning Incorporated (NYSE: GLW) and Pfizer Inc. (NYSE: PFE) today announced the execution of a long-term purchase and supply agreement for Corning Valor® Glass.

The multiyear agreement provides for the supply of Valor Glass vials to a... More